Venture Capital

Elysium Health's new Creatine+ isn't just a supplement; it's a signal of a massive structural shift where human vitality becomes a core economic asset.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

Chaka Khan's partnership with HarbourView isn't just a deal; it's a look into the future of music, where finance and artistry create a new kind of legacy.

While firms spend billions on tech, a new book argues the biggest data breaches stem from leadership gaps and process failures. Is your boardroom the real front line?

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

Lundin Gold just spun off its silver asset into a new company, LunR Royalties, rewarding shareholders with a special dividend. What does this mean for both firms?

Amedea Pharma's Medical Innovation Olympics isn't just a contest; it's a data-driven crucible for new treatments, with longevity medicine taking center stage.

Northern 2 VCT holds dividends steady despite an NAV dip, celebrating a major IPO while facing new principal risks from AI and UK tax policy changes.

Despite a dip in NAV, Northern Venture Trust raises £30M and maintains dividends, bracing for the impact of a major VCT tax relief cut on UK startups.

Dynasty Financial Partners acquires consulting firm Optima Group, betting that a fully integrated platform of tech, capital, and strategy is the future of RIA support.

An exclusive Florida summit reveals a power shift in sports finance, where athletes are no longer just players but owners, and family offices are the new kingmakers.

With $850M in new capital, Base10 Partners doubles down on its 'Real Economy AI' thesis, proving that automating traditional industries is venture's next frontier.

With an $80M Series B led by Sky9 Capital, PhoenixAI is tackling the critical data bottleneck slowing enterprise AI, offering a new database for autonomous agents.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

With giants like BlackRock ranked alongside pioneers like Hyperliquid, Fortune's inaugural Crypto 100 signals a new era of legitimacy and institutional embrace.

A major financial outlook warns that geopolitical fragmentation, stubborn inflation, and a new AI arms race are creating a new reality for investors.

China's POP Culture Group reports a 141% revenue surge, fueled by digital. But as live events wane, can its IP-focused strategy win in a market of giants?

The asset manager's May report reveals $3.3B in net inflows, driven by a major target date fund win, underscoring its market resilience and leadership.

Micron's appointment of Dr. Alexis Black Björlin, an AI and cloud veteran, signals a strategic pivot to deepen its role in the future of intelligent infrastructure.

As Dubai's property market matures, IPS 2026 emerges as more than a showcase, creating a vital ecosystem where global capital meets next-gen urban innovation.